Pulmatrix, Inc. (PULM)
 NASDAQ: PULM · Real-Time Price · USD
 4.825
 -0.105 (-2.13%)
  At close: Nov 3, 2025, 4:00 PM EST
4.880
 +0.055 (1.14%)
  After-hours: Nov 3, 2025, 4:00 PM EST
Pulmatrix Revenue
Pulmatrix had revenue of $3.00K in the twelve months ending September 30, 2025, down -99.97% year-over-year. In the year 2024, Pulmatrix had annual revenue of $7.81M with 6.96% growth.
Revenue (ttm) 
 $3.00K
Revenue Growth 
 -99.97%
P/S Ratio 
 5,941.05
Revenue / Employee 
 $1,500
Employees 
 2
Market Cap 
17.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 7.81M | 508.00K | 6.96% | 
| Dec 31, 2023 | 7.30M | 1.23M | 20.21% | 
| Dec 31, 2022 | 6.07M | 902.00K | 17.45% | 
| Dec 31, 2021 | 5.17M | -7.47M | -59.09% | 
| Dec 31, 2020 | 12.63M | 4.72M | 59.72% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 64.24B | 
| AbbVie | 59.64B | 
| Eli Lilly and Company | 59.42B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Novo Nordisk | 49.11B | 
PULM News
- 18 days ago - Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets - PRNewsWire
 - 3 months ago - Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets - PRNewsWire
 - 6 months ago - Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets - PRNewsWire
 - 6 months ago - PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM - Business Wire
 - 8 months ago - Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets - PRNewsWire
 - 1 year ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders - Accesswire
 - 1 year ago - Pulmatrix and Cullgen Announce Proposed Merger - PRNewsWire
 - 1 year ago - Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire